HSM Helius Medical Technologies Inc

Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights

Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights
EN
14/10/2020

Underlying

HSMHelius Medical Technologies Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Helius Medical Technologies Inc

 PRESS RELEASE
Free
HSM Helius Medical ...

Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansio...

Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation NEWTOWN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), today announced the filing of its U.S. Food and Drug Administration (FDA) 510(k) submission for the PoNS (Portable Neuromodulation Stimulator) device label expansion seeking an indication for gait and balance deficit in patients with chronic stroke symptoms. The submission w...

10h / 26m 1 EN
 PRESS RELEASE
Free
HSM Helius Medical ...

Helius Announces Positive Outcome of the Portable Neuromodulation Stim...

Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance defi...

July 21, 2025 1 EN
 PRESS RELEASE
Free
HSM Helius Medical ...

Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Li...

Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Ru...

July 9, 2025 1 EN
 PRESS RELEASE
Free
HSM Helius Medical ...

Helius Medical Technologies Announces Reverse Stock Split

Helius Medical Technologies Announces Reverse Stock Split NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on June 30, 2025. Beginning on July 1, 2025, the Company’s common stock will trade on The Nasdaq Capital Market on a split adjusted basis. At the Company’...

June 27, 2025 1 EN
 PRESS RELEASE
Free
HSM Helius Medical ...

Helius Medical Technologies, Inc. Announces Claim Authorization by Cig...

Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device - CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neu...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch